Rituxan associated with PML, warns US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2007年 / 1133卷 / 1期

关键词：

Health Care; Systemic Lupus Erythematosus; Viral Infection; Effective Treatment; Care Provider;

D O I：

10.2165/00128415-200711330-00006

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] US FDA warns of hypericum/indinavir interaction
[J]. Reactions Weekly, 2000, 789 (1) : 2 - 2
[2] PML problems loom for Rituxan
Acton, Malorye Allison
[J]. NATURE BIOTECHNOLOGY, 2010, 28 (02) : 105 - 106
[3] PML problems loom for Rituxan
Malorye Allison
[J]. Nature Biotechnology, 2010, 28 : 105 - 106
[4] US FDA warns about ibuprofen and aspirin interaction
[J]. Reactions Weekly, 2006, 1119 (1) : 2 - 2
[5] US FDA warns Pfizer over tardy pharmacovigilance
[J]. Reactions Weekly, 2010, 1306 (1) : 2 - 2
[6] US FDA warns against fenfluramine/phentermine combination
[J]. Reactions Weekly, 1997, 662 (1) : 2 - 2
[7] Risk of differentiation syndrome with enasidenib, warns US FDA
[J]. Reactions Weekly, 2018, 1732 (1) : 4 - 4
[8] US FDA warns of unauthorised devices for diabetes control
[J]. Reactions Weekly, 2019, 1755 (1) : 8 - 8
[9] US FDA warns of heart issues, death with clarithromycin
[J]. Reactions Weekly, 2018, 1692 (1) : 7 - 7
[10] US FDA warns of increased myopathy risk with Zocor
[J]. Reactions Weekly, 2010, 1294 (1) : 1 - 1

← 1 2 3 4 5 →